Jardiance®
Empagliflozin is an SGLT2 inhibitor originally developed for diabetes, now with strong evidence for heart failure and renal protection.
| Dosage Form | Oral Tablet (Film-Coated) |
| Strength | 10 mg, 25 mg |
| Storage | Store at 25°C. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
Type 2 diabetes; heart failure (with or without diabetes); chronic kidney disease.
Inhibits sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubule, reducing glucose reabsorption, promoting glycosuria, and providing cardio- and nephroprotective effects.
Each Burrard Pharmaceuticals technology transfer package for Empagliflozin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.